Project Brief

The Lonza Endotoxin Phase 2 Project is a new, high-tech manufacturing facility designed to produce Lonza’s BLA (FDA) regulated Endotoxin products. The facility will have the capacity to produce lyophilized vials annually to meet market demand for Lonza’s Endotoxin product lines up to 2032. The project also integrates critical infrastructure including Water for Injection (WFI), Pure Steam, Compressed Air, and Process Waste Neutralization systems, along with cold storage and office space. This high-tech facility exemplifies Lonza’s commitment to quality, and global health advancement.